Oppenheimer Downgrades Myriad Genetics (MYGN) to Perform
More News related to MYGN
- Myriad Genetics to Present at the 21st Annual Piper Jaffray Health Care Conference
- Morgan Joseph Upgrades Myriad Genetics (MYGN) to Hold; Expect Positive Sales
- Myriad Genetics to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Myriad Genetics (MYGN) Misses Q1 EPS by 3c
More News related to Downgrades
- Wells Fargo Downgrades Boardwalk Pipeline Partners, L.P. (BWP) to Market Perform; Valuation Call
- Airline Stocks Rising Again as Morgan Stanley Upgrades Sector to 'Attractive' (AMR, UAUA, ALK, ALGT)
- Morgan Stanley Cuts US Healthcare Facilities Sector to 'Cautious'; Starts LPNT at Overweight, THC, UHS at Underweight
- Credit Suisse Downgrades Mechel OAO (MTL) to Underperform
- Goldman Sachs Downgrades Constellation Brands (STZ) to Sell
Oppenheimer downgrades Myriad Genetics (Nasdaq: MYGN) from Outperform to Perform.
To see more analyst ratings on MYGN Click Here.
Myriad Genetics, Inc. is a healthcare company focused on the development and marketing of molecular diagnostic and therapeutic products.
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
